Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Faster, cheaper scans could revolutionize cancer radiation planning

NCT ID NCT07185958

Diagnosis Sponsor: Aalborg University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will test whether a special CT scan (dual-energy CT) can be as good as MRI for mapping tumors and healthy organs before radiation therapy. Researchers will enroll 80 people with brain, bone, head/neck, or lung cancer. If DECT works well, it could save time and money compared to MRI.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dual-energy CT (DECT) scan and iodine-based contrast agent
What this could lead to
If successful, DECT could become a faster, cheaper alternative to MRI for planning radiotherapy, improving access and efficiency.
What could go wrong
This is an early-stage study with only 80 participants, and DECT may not prove as accurate as MRI for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cancer patients referred for radiotherapy at Aalborg University Hospital, Denmark. For the 'DART Bone (SBRT)' cohort, patients are also referred for radiotherapy at Odense University Hospital and Copenhagen University Hospital, Herlev and Gentofte, Denmark

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ECOG performance status (PS) 0-2 * Assessed to be able to complete the protocol scanning regime * Referred for RT * For head and neck cancer patients, a PET/CT scan must have been performed during the diagnostic evaluation for cancer * Signed informed consent Exclusion Criteria: * Pregnancy * Previous RT in the same anatomical area now referred for RT * Previous surgery in the same anatomical area now referred for RT * Participation in conflicting protocols * If relevant for the protocol scanning regime: Allergic to contrast agent * If relevant for the protocol scanning regime: Contraindication to iodine-based contrast agent for CT (as determined by the physician) * If relevant for the protocol scanning regime: Contraindication to Gadolinium-based contrast agent for MRI (as determined by the physician) * If relevant for the protocol scanning regime: Contraindication for MRI (pacemaker, metal, non-MRI, compatible implants etc.) * Incapable of understanding the patient information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer head and neck cancer Head and Neck Neoplasms lung cancer lung neoplasm metastatic carcinoma in the bone metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone metastases Brain metastases Head and neck cancer Lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, 9000, Denmark

  • Copenhagen University Hospital Herlev and Gentofte

    Herlev, 2730, Denmark

  • Odense University Hospital

    Odense, 5000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.